secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K12G3
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001104659-25-052750
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.03, 8.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene completes redomestication to Switzerland, renamed BeOne Medicines Ltd.
------------------------------------------------------------------------------

- Effective May 27, 2025, BeiGene continued from Cayman Islands to Switzerland, becoming BeOne Medicines Ltd.
- New Swiss Articles and Organizational Regulations govern shareholder rights; ADSs continue on Nasdaq under ONC.
- Executive employment agreements executed with CEO Oyler ($1.133M base), President Wu (RMB 6.0M), CFO Rosenberg ($660K), R&D head Wang (RMB 4.59M), and GC Lee ($654K).
- Amended deposit agreement with Citibank and new indemnification agreements for directors and officers adopted.
- Ordinary shares listed on HKEX (06160) and Shanghai STAR Market (688235) remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000110465925052750/0001104659-25-052750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000110465925052750/tm2515777d13_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer